ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
CytoDyn Inc (QB)

CytoDyn Inc (QB) (CYDY)

0.1666
0.00
(0.00%)
Closed March 28 04:00PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
0.1666
Bid
0.15
Ask
0.55
Volume
-
0.00 Day's Range 0.00
0.1456 52 Week Range 0.418
Market Cap
Previous Close
0.1666
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
3,095,325
Shares Outstanding
979,527,000
Dividend Yield
-
PE Ratio
-2.09
Earnings Per Share (EPS)
-0.08
Revenue
-
Net Profit
-79.82M

About CytoDyn Inc (QB)

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
CytoDyn Inc (QB) is listed in the Pharmaceutical Preparations sector of the OTCMarkets with ticker CYDY. The last closing price for CytoDyn (QB) was $0.17. Over the last year, CytoDyn (QB) shares have traded in a share price range of $ 0.1456 to $ 0.418.

CytoDyn (QB) currently has 979,527,000 shares outstanding. The market capitalization of CytoDyn (QB) is $166.52 million. CytoDyn (QB) has a price to earnings ratio (PE ratio) of -2.09.

CYDY Latest News

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 424B3 - Prospectus [Rule 424(b)(3)]

​Filed pursuant to Rule 424(b)(3)Registration No. 333-276912 PROSPECTUS SUPPLEMENT NO. 1(to Prospectus dated February 22, 2024)​​​​Up to 141,019,099 Shares of...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Filed pursuant to Rule 424(b)(3)Registration No. 333-272815 PROSPECTUS SUPPLEMENT NO. 8(to Prospectus dated October 11, 2023)​​​​Up to 205,652,848 Shares of Common...

Form 424B3 - Prospectus [Rule 424(b)(3)]

​​Filed Pursuant to Rule 424(b)(3)Registration No. 333-276912Up to 141,019,099 Shares of Common StockThis prospectus relates to the resale of up to 35,792,347 shares of our common...

Form 3 - Initial statement of beneficial ownership of securities

EXHIBIT 24   LIMITED POWER OF ATTORNEY   The undersigned hereby appoints each of Tyler Blok, and/or Nathan Fox signing singly, as the undersigned's true and lawful attorney-in-fact...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Filed pursuant to Rule 424(b)(3)Registration No. 333-272815 PROSPECTUS SUPPLEMENT NO. 7(to Prospectus dated October 11, 2023)​​​​Up to 205,652,848 Shares of Common...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.00593.671437461110.16070.170.160113063390.16423746CS
4-0.0234-12.31578947370.190.280.160131614980.20697214CS
12-0.0384-18.73170731710.2050.280.150530953250.1853374CS
26-0.0086-4.908675799090.17520.4180.145626025120.19684002CS
52-0.2284-57.82278481010.3950.4180.145619853840.21482812CS
156-2.1334-92.75652173912.34.220.145622672420.81884717CS
260-0.3334-66.680.510.010.145628611712.18139043CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 17.29
(264.00%)
503.83k
BCGBinah Capital Group Inc
$ 19.19
(102.00%)
138.05k
PIKKidpik Corporation
$ 5.36
(63.91%)
1.36M
SSKNStrata Skin Sciences Inc
$ 0.66
(48.35%)
2
PEGRProject Energy Reimagined Acquisition Corporation
$ 11.58
(33.72%)
338
WAVDWaveDancer Inc
$ 2.93
(-18.61%)
10
UGROUrban Gro Inc
$ 1.48
(-18.46%)
393
INOInovio Pharmaceuticals Inc New
$ 10.65
(-18.27%)
33
WETHWetouch Technology Inc
$ 1.85
(-18.14%)
1.99k
SOBRSOBR Safe Inc
$ 0.41
(-18.00%)
1.49k
KTRAKintara Therapeutics Inc
$ 0.1182
(32.07%)
10.95M
AKBAAkebia Therapeutics Inc
$ 2.31
(3.13%)
3.62M
GMDAGamida Cell Ltd
$ 0.0491
(-17.06%)
1.66M
CISSC3is Inc
$ 0.036
(-5.76%)
1.59M
PIKKidpik Corporation
$ 5.35
(63.61%)
1.36M

CYDY Discussion

View Posts
Learning53 Learning53 2 hours ago
Thank you ;)
👍️0
djjazzyjeff djjazzyjeff 3 hours ago
"streetology and proper Investments" and yet you gave money to Nader. I smell bullshit get lost
👍️0
kgromax kgromax 4 hours ago
During these 14 years, the SPY has gone +411% while your investment has gone -70%.

With multiples, the same investment in the SPY would have produced x16.9 more capital today.

That's the reality about pump & dump stocks: all the retail investors that didn't dump into the high end up holding the bag.
👍️0
Niknak1 Niknak1 6 hours ago
14 + years I've been involved in this stock. I gave n a d d e r when he first took the position as far going out and raising money when he was just a nobody. The sum of 95,000. At a stock price of $0.55 a share. Oh I bought some more after that. And I actually don't know why I'm really putting this out for public knowledge but that's fact, I did that. I still am a firm believer that the science of this drug works. I know there's a term if you want to be a sucker be a quiet one and I have been for many years. But what frustrates me so much is listening to all of the b******* that goes back and forth back and forth. I'd say about 90%. If not more I might add none of you make a lot of sense. Basically every one of you at one time or another if not more I'd like to kick all of your ass. You make me puke it's so frustrating to listen to all of your as I indicated previously b*******. You sound like a bunch of high school dropouts. And I'm sure there's several of them on this board. As a matter of fact I am one of them. But also an extremely successful one. I made my money from streetology and proper Investments. Yes in a matter of about 4 hours I went from on paper 2.2 million down to point 1 million. Ouch that hurt. But I know a lot of other people experience that same hurt. Ouch ouch. That's all I haven't got any time to waste at my age let alone wasting my time with the majority of you idiots.
👍️0
djjazzyjeff djjazzyjeff 7 hours ago
Shut up loser
🤡 2
The Dark KnaDDir The Dark KnaDDir 8 hours ago
Scott Kelly took a nice hiatus from his medical career where for a few years he smiled like a fool into the camera and said "back to you Nader" for which he was paid by the longs $3M a year in total comp, about 10x what he made as a doctor. Yes, his comp ultimately came from the longs buying up inflated cydy shares, a good chunk of which he dumped in May 2020 during the HIV BLA fiasco. Nader also dumped his shares during this time, and he is charged with insider trading for doing so. Interestingly, Kelly avoided having these same charges even though he was Nader's boss in name as Chairman Of the Board.
👍️0
$5.95akadawson-m $5.95akadawson-m 8 hours ago
Grow up. Be an adult.
👍️ 2
$5.95akadawson-m $5.95akadawson-m 10 hours ago
As Janice Shell pointed out about autocorrect, you should heed it too. There is nothing funny about your comment. If you’re going to be a representative on this board, stay in your adult.
👍️ 4
djjazzyjeff djjazzyjeff 11 hours ago
Loser longs obsessed with their failed investment search day in and day out for some sign any sign that they haven't been completely had. But guess what idiots, youve been had.
👍️ 1 🤡 1
Upside08 Upside08 15 hours ago
I heard it’s great for crotch rot that bashers have due to sitting in a chair in the basement day after day.
👍️ 3
djjazzyjeff djjazzyjeff 15 hours ago
Leronlimab makes a good deodorant for stinky pits
👍️0
kgromax kgromax 16 hours ago
It’s a pre-revenue biotech company.
It's a post-failure biotech company.

Checks all the boxes:
- Massive debt, dilution and lawsuits which make it impossible to raise with legit actors
- Crazy execs turnover with fat paychecks
- All phase 3 trials failed
- Inventory and patents phasing out

You are holding the bag.
🤡 1 🤮 1
bwolfy2002 bwolfy2002 17 hours ago
It’s a pre-revenue biotech company. The ability to sell its product is based upon a regulatory process. One cannot have revenue if they cannot sell their product yet. There are many biotechs that are working towards the approval necessary to sell their products. This is the truth and the facts about the status of CYDY right now. But you know all this because:

The only sensible thing you’ve said is that pre-revenue companies are not in your purview/wheelhouse. You’re flapping your gumbs in a place YOU ADMIT you do not belong and would be true even if you didn’t admit it. Then you wonder why people take offense to your asshole musings. Weird….
👍️ 1
kgromax kgromax 18 hours ago
Loserlibag?

It's saline, and it does cause diarrhea.

Has been around since the 90's, without any published phase 3 trial success in more than 20 years of existence.

A failure.

Everything else is hearsay, unproven opinions, rumors, and data dredging.
In one word: manipulation for the gullibles.

As an exemple, misiu143 for example has participated directly to a pump operation on ZeroHedge. Or, after denying for months having received a "sweet deal" from the company in the past, has finally recognized having had one. Yet she keeps pretending she is there "only for the drug".
👍️ 1
fung_derf fung_derf 18 hours ago
Well this response makes no sense. My post had zero fallacies as penny stocks sales aren't about selling earnings, its about dumping shares, and considering this company has yet to have sales or earnings, the entire business is taking higher priced shares and dumping them on others.
As for illegally naked shares.....now you're just posting on penny stock mullet folklore.
Considering history has shown this all to be true, how you all consider to argue otherwise just makes you look ignorant.
Out of curiosity, how many employees does this company now have?

BTW, the fact that others just respond with insults rather than facts tells the whole story of this stock. Just deny facts and hope. Oh, and occasionally, if you can, dump your losses onto someone else.
And THIS is why I stick around here. To prevent newbies from believing your nonsense.
👍️ 1 🤡 1
Since 2012 Since 2012 19 hours ago
IKR, that was the dumbest post I have read in a long time
👍️ 1
Since 2012 Since 2012 19 hours ago
Again, did you find out if that hold got lifted
👍️ 1
justdafactss justdafactss 19 hours ago
Was Dr. Lalezari ever a Principal Investigator on clinical trials conducted for Merck, Bayer, Pfizer, and Roche?
Dr. Lalezari served as Principal Investigator on clinical trials conducted for Merck, Bayer, Pfizer, and Roche
https://www.biospace.com/article/releases/cytodyn-selects-b-quest-clinical-research-b-for-next-trial-of-hiv-aids-immune-therapy-/
Or is that a complete and total LIE?

Did you sell any CYDY shares below $40? You said you wouldnt and that was a lie.

Did CYDY release an SEC 8K filing regarding a hold being lifted?

Yes or No?
🤡 2
bwolfy2002 bwolfy2002 19 hours ago
What an absurd notion… how someone so illogical can be so cocky is the real joke here. Let’s ignore all the more glaring fallacies here and go with the fun one that is just barely less ridiculous than your post: I only sold shares to the 10s of millions of illegally naked shorts, so no one was “stuck” with them as they had already and illegally sold the shares without putting anything up.
👍️ 3
$5.95akadawson-m $5.95akadawson-m 19 hours ago
But what about Leronlimab? Do you know anything - anything about it?

We all know the insider's enrichment and all of your empty stats. What about the efficacy of Leronlimab?

You are the top-gun of old and nothing information.
👍️ 3
misiu143 misiu143 19 hours ago
HAHAHAHAHA....

Is that the quality of posts you are paid for.
Mostly the ONLY thing in particular message board you presenting !! Is that the only information about the drug here you have ??

Last 5.95 from me today.

All imo.

GLTA longs.
👍️ 1
fung_derf fung_derf 20 hours ago
When one uses quotation marks in English, they actually USE the quote....

attacking her personally

vs

" Attacking her personality "

Really VERY funny.

You see how this works??
Of course I knew you'd never apologize. This would show you were wrong, and it has been proven again and again that you will never admit to anything wrong.
🤮 1
fung_derf fung_derf 20 hours ago
Sorry, I’m not anywhere near red, remember June 2020, something you can only dream of

Do you really not grasp that IF you made money, you did so due to a pump and dump??
If you think its perfectly fine to make money due to criminal activity, well this says a lot about you.
If you are at a bank when a robbery occurs and you stuff some of the loose $100 bills in your shirt, are you an accessory or just profiting from a crime?
Considering the company STILL has no approved product after all these years, its a failure...this is kind'a black and white scenario. How you people see yourselves as the good guy is beyond me. Ya know when you sold your shares for a profit at a highly inflated price, that someone else got stuck with them, right?
This wasn't investing, this was taking advantage of the CEO's fraud. And you are on here bragging about it.
👍️ 1 🤡 2
misiu143 misiu143 20 hours ago
Learning , did you read this ..You are a CRIMINAL Dr NP , did you know that ?? .

How do you like this diagnoses !!!!!

All imo.

GLTA longs.
👍️0
fung_derf fung_derf 20 hours ago
perhaps you should inform "Learning" of this, being that he's on here defending him.
I find it intriguing you only call out "certain" posters.
Are you interested in truth, or finding someone to blame for your misjudgements?

Nader did buy the company which saved it from the scrapyard, none of us would be here if he hadn’t, but that’s about as far as he could take it, he did do some good helping people get the drug, but he also got greedy and here we are, most longs don’t agree with what he did they just don’t say much because of the criticism they get

Seriously??? How do you explain his previous criminal actions?
🤡 3
fung_derf fung_derf 20 hours ago
I have always figured you were an insider. Now you are defending a known criminal....well not just defending him....speaking for him....which, there is a likely chance you ARE him.
🤡 3
misiu143 misiu143 20 hours ago
" Attacking her personality "

Really VERY funny.

GLTA longs..
👍️0
fung_derf fung_derf 20 hours ago
Shouldn't you apologize to Janice for first off, attacking her personally before she ever posted here, then attacking her for being here?
🤡 1 🤮 1
fung_derf fung_derf 20 hours ago
Apparently, no one on here is influencing the stock price any longer. The fact that you are bothered more by people who DON'T have an agenda, but have been correct, vs the people who have been lying to you, is rather odd.
In my opinion, it would be dumb to short a penny stock, but even if I did, if the share price keeps falling, and someone had warned you, why would you have animosity towards them? And what type of criminal ever comes out publicly to tell you they are screwing you? Isn't it much more likely, they are the ones telling you to buy more or hold so they can dump?
Using your head while investing is an investment strategy that people outside of penny stocks like to use.


So much wisdom on this board who are not shareholders or shorts that care about current investors. They have so much care, they have time out of their lives everyday to post here regularly
👍️0
kgromax kgromax 20 hours ago
Cytoscam PRs have enriched only their insiders

So many lies, more particularly the questions not asked and never answered.

But please take that stock ride to zero LOL

Looooooserlibag
🤡 1
JustDaTruthB JustDaTruthB 21 hours ago
FREQUENTLY ASKED QUESTIONS

Last updated February 2024

What operational and financial adjustments did the Company make in fiscal year 2023?



During FY23, the Company made significant reductions to its workforce, cash burn rate, and operating expenses, to preserve its resources and use them where they are most needed. This transformation consisted of reducing our force of full-time employees by approximately 70%, adding five part-time employees, and leveraging experienced consultants and advisors on a part-time basis. This, along with other expense reduction measures, led to significant improvements in the Company’s cash burn, G&A expense, and R&D expense run rates. Compared to the prior fiscal year, in FY23 we saw decreases in the Company’s cash used in operating activities of 68%, decreases in G&A expense of 61%, and decreases in R&D expense of 90%.

By restructuring our workforce and electing to retain specialized consultants where possible, we believe we have significantly enhanced our regulatory, clinical, and medical capabilities, and further assembled a team that places the Company in the best position to be successful. We are optimistic that the latest clinical hold submission to the FDA will result in the lifting of the clinical hold. If successful, our current team stands ready to implement the best strategies to maximize shareholder value in the near- and long-term.




What is the status of the clinical hold?

CytoDyn Announces FDA Has Lifted Clinical Hold (press release dated February 29, 2024)



What is the short-term development plan for leronlimab following the resolution of the clinical hold?



The Company has continually evaluated the various indications for leronlimab, and worked to strategically determine how to best focus and advance each indication – whether in-house and/or through strategic partnerships. This work did not cease during the clinical hold process.

Following the resolution of the clinical hold, we will continue to focus on a multiple therapeutic development approach to leronlimab. We have already been working toward eventual decisions as to the most opportunistic, least capital-intensive manner to develop and create value through various means for leronlimab, identifying strategies that are time- and cost-effective and create the opportunity for non-dilutive financing opportunities such as license agreements, co-development, partnerships, etc. For example, KOLs consulting with the Company identified a clinical trial in the HIV space they feel strongly about that will help patients and can be conducted in a time- and cost-effective manner. Further, we will continue to evaluate pre-clinical combination therapy trials in MASH and oncology. Positive developments in the foregoing initiatives could also result in more substantive interest from third parties by way of licensing and collaboration agreements, joint development initiatives, and other partnership opportunities.

What is the current status of the longer-acting therapeutic project?

Early in 2023, the Company entered into a partnership directed toward developing a long-acting therapeutic to bolster our existing IP portfolio and patent protection with the goals of attracting partnership opportunities, preserving and increasing the value of our patent portfolio, and creating additional shareholder value.

The partner company is an experienced drug development company and uses generative artificial intelligence (AI), among other technologies, in its development activities. If successful, such a modified therapeutic would require less frequent injections for patients on drug, furthering the convenience and overall marketability of the product. Working with a company with established AI-capabilities allows for an expedited and robust development path for this modified, longer-acting therapeutic for the Company.

How does the Company make decisions as it relates to executive compensation?



Each year, the Company’s Board of Directors reviews and appoints at least three independent members of the Board to serve on a compensation committee (the “Compensation Committee”). Among other duties, the Compensation Committee oversees incentive, equity-based and other compensatory plans for executive officers of the Company.

On an annual basis, the Compensation Committee evaluates the Company’s overall compensation philosophy and determines base salaries and other forms of compensation to be paid to executive officers, including cash incentive compensation and grants of stock options and other stock-based awards, which are all disclosed in the Company’s annual proxy statements. The Compensation Committee’s decisions are based on (annual) recommendations received from an independent executive compensation advisory firm retained by the Compensation Committee. The independent compensation consultant analyzes peer companies and other benchmarking and comparison data, and then makes recommendations as to the competitiveness of the Company’s executive compensation program, and a proposed mix of compensation elements. The above process ensures that the Company and Compensation Committee’s practices are in-line with industry standards, and companies of similar size and financial condition. This process also helps ensure that the Company is able to attract and retain talented key employees.

At the 2019 Annual Meeting of the Company, our stockholders approved the Board’s recommendation that an advisory vote on executive compensation be conducted annually. Accordingly, each fiscal year, the shareholders are asked to place an advisory vote as to the compensation of our executive officers.

Additional information as it relates to responsibilities and processes of the Compensation Committee is set forth in its charter and director and executive officer compensation policy, which are posted on our website under Governance Documents. Additional, more-detailed information in relation to the compensation paid to executive officers can be found in the Company’s required SEC filings, including the Company’s Definitive Proxy Statement filed on September 25, 2023.

What is the current status of the Amarex litigation effort?



In July 2023, the Company took the next step towards holding Amarex, its former clinical research organization (CRO), accountable for its numerous failures in relation to clinical trial management and regulatory services it was supposed to have provided to CytoDyn. The Company is seeking damages in excess of $100 million from Amarex in this action. We have fully funded the Company’s counsel, Sidley Austin LLP, for this litigation effort in advance, which allows them to take all steps necessary to maximize the Company’s recovery from Amarex. The final arbitration hearing is set to commence August 12, 2024. We would then expect the arbitrator to issue their final order sometime in the weeks following the conclusion of the final hearing, perhaps in late September 2024. We are confident in our case and have one of the preeminent litigation firms in the world representing the Company in this proceeding. We will continue to vigorously pursue this matter.

What is the status of the new communication strategy?

The Company is in the process of making a marked shift in its communications with stakeholders. These renewed engagement efforts will be clear, concise, measured, and compliant with pertinent regulatory requirements. We will continue to update shareholders as required with material information and developments via our SEC filings, but we also anticipate communicating more frequently with investors via direct communications. We will also communicate more frequently with the market at large, and we actively review and respond to investor inquiries.

You already may have noticed a change in our responsiveness with investors via the Company’s IR email account (ir@cytodyn.com) over the past several months. Additionally, we actively review all investor communications for recurring themes which helps better inform the Company on what is most important to current and potential investors. We are also in the process of setting up a FAQ section on the Company’s website where we intend to post and respond to the most important questions. This FAQ page will be updated on a regular basis.

Note Regarding Forward-Looking Statements

This Frequently Asked Questions supplement contains forward-looking statements relating to, among other things, future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and/or our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review the Annual Report on Form 10-K for the fiscal year ended May 31, 2023, including in the sections captioned “Forward Looking Statements” and “Item 1A. Risk Factors”, as later supplemented by our Form 10-Q for the quarter ended August 31, 2023, in the section captioned “Item 1A. Risk Factors”. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments.
👍️ 3 🤑 1
Since 2012 Since 2012 21 hours ago
Did you find out if that hold got lifted
👍️ 3
justdafactss justdafactss 21 hours ago
CYDY still stuck in da 16s?

LAUGHING
🤡 2 🤮 1
kgromax kgromax 1 day ago
I do think there is a promising future for Leronlimab as a placebo or an anti-constipation drug.

All published statistical tests point toward this.

Too bad this required hundred of million of dollars of wasted mom & pop savings!
🤡 1
kgromax kgromax 1 day ago
Lol how many relationships do you think CYDY has disrupted? Lolllllllllll
I have been contacted already by 2 people who have ruined their couple with Loserlibag.
They thought they would make their family rich, as a surprise gift to their spouse. Of course they lost most of their family savings in the scam. Then, they have disappeared after recognizing “having been taught an expensive lesson”. I guess the spouse didn’t enjoy the outcome.
👍️0
djjazzyjeff djjazzyjeff 1 day ago
If you snort the leronlimab it fixes ADHD faster just fyi
🤡 1
Learning53 Learning53 1 day ago
As mentioned "cogitate"
www.visualcapitalist.com/cp/worlds-50-largest-pharmaceutical-companies/

Or (suggestion) go "meta."

(Regrettably, such a powerful concept "purloined")

the compulsion to drop some bread-crumbs is intense... but like intermittent fasting - one must look at, savor at a distance but move on.

And Leronlimab might be a fine exemplar of a different "conceptualization"...there's today's breadcrumb (succumbed to temptation, LOL)

IMO

***
👍️ 2
djjazzyjeff djjazzyjeff 1 day ago
Use some leronlimab as filler those wrinkles will vanish
🤡 2
Learning53 Learning53 1 day ago
Time, time, TIME!!!!! Is of the essence! the "nimble, multiple fingers" of the BP fraternity frantically burning the midnight oil to replicate a patentable "similar" to Leronlimab. CytoDyn has already demonstrated (enough) and we're not dealing with "lame brains." If they weren't as concerned, we wouldn't experience all the extraordinary counter-measures impeding Leronlimab's acceptance. I'm questioning the standard wisdom of calmly following the myriad steps to "prove" leronlimab effective by FDA standards...to eke out an eventual (and YOU don't expect further roadblocks?) approval.

A process dedicated to incinerating time we don't have!

I am NOT dissing Dr. J, but suggest an alternate strategy:
>benefitting by" throwing a juicy piece of raw meat to a wolf."
Pick out a tempting "indication," limit the damage by enlisting Sidley Austin to legally confine/define the usage/grant, and offer it at a pittance to its actual value. Right now the BP fraternity have obviously banded together to "stonewall" Leronlimab's progress.

But...there's probably a member of the BP crowd facing a faltering drug line-up and less than delicious balance sheet, which might be willing to "break the chain," with sufficient motivation!

Which is the weakest link...?

Here's the map: www.visualcapitalist.com/cp/worlds-50-largest-pharmaceutical-companies/

***
By the way - the graphic suggests another provocative idea. "Cogitate"

***
Throw the designated target a juicy (but limited) indication and let them revel in their unexpected profits after they gain almost immediate acceptance with their buddies at the FDA... resulting in a Leronlimab approval further creating an avenue for off-label usages.

To wit..Envious BP members, noticing, might be clamoring for another "toss of the red meat," but this time (having gained their attention) at more equitable terms to CytoDyn.

In other words >> use BP as our initial mechanism for approval...and save some really "juicy chunks" for the folks - "longs" here.

If we "diddle about" they'll move on without us, so let's use the greed of BP to "Break the blockade!"

***
For a long time we've been the chicken running into a wall...perhaps its time to consider "using" BP to our own ends, by joyously opening the cage to "use us."
***
Let's fracture the bond that binds, as others envy a a billion dollar addition to a competitor's bottom line while they stood there, arms linked, and statuesque >>> "they let the prize be swiped from under their nose by a "brother company."

Use their greed against them.

Time for Dr. J to "have some fun."

IMO

IMO and LOL
👍️0
$5.95akadawson-m $5.95akadawson-m 1 day ago
Who cares if it was in “Nature.” The writer (s) of the article are reaching. They have no proof YET! That’s why, they’re hedging. If they were to say Definitively without proof, they would be in the same Nader camp.

That’s why there are Phase trials!

I know. And members of this board have found out the hard way and are the butt of a lot of jokes.

How about this one:
“Some members of this board have raising hopes that Janice Shell will never post here again.”
👍️ 1
janice shell janice shell 1 day ago
And that was a quotation from the article in Nature. Go elsewhere to worry about "gerund phrases".
👍️ 1
djjazzyjeff djjazzyjeff 2 days ago
Lol how many relationships do you think CYDY has disrupted? Lolllllllllll
🤡 1
The Dark KnaDDir The Dark KnaDDir 2 days ago
This has always been just an insider self-enrichment vehicle from the get, hence the hiring of an utterly unqualified twice convicted felon as CEO way back when. Why would a felon ever be hired by any legit company in the USA? It just doesn't happen....unless you need to use the felon's "work experience".
👍️0
Grip it and Sip It Grip it and Sip It 2 days ago
Blueheel-

As always, a well-reasoned pragmatic comment!

You are one of a few I’m rooting for
👍️ 1
kgromax kgromax 2 days ago
It's an IQ test.

Winners get a Bagholder Gold Medal. And a nice discussion with the wife.
👍️0
djjazzyjeff djjazzyjeff 2 days ago
You been in "wait and see mode" while the share price drops 90%+. If you are still waiting and haven't seen, you're an idiot.
🤡 2
djjazzyjeff djjazzyjeff 2 days ago
How many trials were they running before the hold was lifted? How many are they running now? Is the answer a whopping ZERO for both questions? That's your answer. This is a biotech company, their job is to run clinical trials, not get holds lifted because they were incompetent. God cydy longs are so incredibly stupid. Guess who told you it was just going to come back down? Oh yeah the bashers, who have been right every time. And yet you listened to the pumpers who said it would fly 1000%. That sir, makes you an idiot.
👍️ 1 🤡 1
kgromax kgromax 2 days ago
Being able to discredit all longs in one sentence is no small feat.

👍️ 1
Blueheel1 Blueheel1 2 days ago
It's perplexing that the SP is back down to where it was before the hold was lifted. That just makes no sense to me. I can only assume there is some source of selling pressure that stepped in on the initial price jump. But to say there shouldn't be a higher SP after removing the hold makes no sense to me, as that was a major source of uncertainty for 2 years.

At this point, there are catalysts that could occur at any time (progress / clarity on the Amarex front, partnership with an institution or company, etc.) that would be a catalyst for a higher SP. But, for me - what i'd really like to see is some clarity on a trial beyond just the exploratory trial on inflammation (which won't start until later this year and take 18 months or so). Clearly we would need a partnership on something like that - especially if it's a trial in an area like cancer, which is expensive, unless we were to get a windfall from Amarex.

So, I'm in "wait and see" mode - which i have been in for quite a while. I don't expect a lower SP like some on here - but when we get a catalyst for a much higher price, I just have no clue. Maybe we'll get another call before too long and hear something from JL.
👍️ 1
Monroe1 Monroe1 2 days ago
I love it. They can keep on taking the junk jabs and feeding on official propaganda all they want.
I do have to thank them for the opportunity to load and BE GREEN! It's going to be a really nice run
when it happens.

$CYDY$ 2024
👍️ 3

Your Recent History

Delayed Upgrade Clock